Can Monthly Dosing With Novel GLP-1 Maintain Weight Loss?

— Study on investigational berobenatide demonstrates long-acting benefit of drug

by Gregory Laub, Senior Director, Video, MedPage Today

June 22, 2026

• 2 min read

At the American Diabetes Association annual meeting, updated phase II data from the VESPER program showed that patients who achieved weight loss with a weekly dose of the ultra-long-acting investigational GLP-1 agonist berobenatide could transition to monthly dosing and maintain that trajectory with favorable gastrointestinal (GI) tolerability.